Chugai Pharmaceutical stock

4519 · TSE · JPY

Compare Chugai Pharmaceutical
¥7,263.00Change from previous close: −1.05%Absolute change: −¥77.00

Close · November 18, 2026

Price history

−12.49% over the period

1 year: from ¥8,300.00 (November 18, 2025) to ¥7,263.00 (November 18, 2026), −12.49%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 18, 2026¥7,263.00
October 30, 2026¥6,822.00
September 30, 2026¥6,225.00
August 31, 2026¥6,913.00
July 31, 2026¥6,932.00
June 30, 2026¥7,534.00
May 29, 2026¥7,892.00
April 30, 2026¥8,116.00
March 31, 2026¥8,611.00
February 27, 2026¥10,455.00
January 30, 2026¥8,801.00
December 30, 2025¥8,243.00
November 28, 2025¥8,374.00
November 18, 2025¥8,300.00

At a glance

TickerLandia's take on Chugai Pharmaceutical

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥5,974.00
52-wk high¥10,700.00

−32.12% from the 52-week high

Analysts · 15 analysts

Average target¥8,393.33+15.56% vs. price

Buy 10 · Hold 5 · Sell 0 · Buy

TickerLandia Fingerprint: Chugai Pharmaceutical

Compared with similar companies: very high financial strength.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Chugai Pharmaceutical is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Chugai Pharmaceutical's P/E today is 27.5, below the median of its last 10 fiscal years (32.8; between 14.8 and 43.4 from 2016 to 2025). Chugai Pharmaceutical's P/E (trailing 12 months): 24.1, +31% against the median of a group of 10 similar companies (18.4).

P/E compared with its history

Compared with 10 similar companies

Chugai Pharmaceutical's metrics compared with similar companies
MetricChugai PharmaceuticalPosition in the groupBand
P/E (trailing 12 months)24.1Middle
Forward P/E31.3High
Operating margin48.3%High
ROE25.3%High
Debt/equity0.01Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Chugai Pharmaceutical. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥404.74B

Latest quarter · Q3 2026

Net income

¥143.55B

Latest quarter · Q3 2026

Quarterly net margin

35.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥12.15T
P/E
24.1
EPS
¥306.09
Volume
2.78M
Daily trading
€132.62M
Dividend yield
2.93%

How Chugai Pharmaceutical is changing

All results
  • Revenue grew 9.8% a year on average over the last 5 years

  • Operating margin rose from 42.3% to 47.6%

  • Profits turn into cash: free cash flow equal to 91% of net income

Returns

Chugai Pharmaceutical returns with dividends

¥1,000 invested in Chugai Pharmaceutical 5 years ago, on November 18, 2021, would be worth ¥1,960 today with dividends reinvested: +96.02% in total, +14.41% per year. On price alone it would be ¥1,757 (+75.73%).

PeriodChugai PharmaceuticalNikkei 225¥1,000 becomes
1 month+14.67%−9.15%¥1,147
6 months−7.89%−2.91%¥921
Year to date−11.89%+17.16%¥881
1 year−10.17%+21.10%¥898
3 years+58.85%+76.65%¥1,589
5 years+96.02%+99.26%¥1,960
10 years+696.37%+228.25%¥7,964

Over the last 6 months it has done better than 17% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment

The chart in detail

Chugai Pharmaceutical: technical analysis

Chugai Pharmaceutical shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 30.5% below its all-time closing high (¥10,455.00, February 27, 2026).

Trend
No clear trend
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
−5.93%

Support and resistance

Price areas where Chugai Pharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance¥7,995.50+10.09%4 touches, last on July 3, 2026
  2. Resistance¥7,705.00+6.09%2 touches, last on June 16, 2026
  3. Resistance¥7,391.50+1.77%2 touches, last on November 5, 2026
  4. Last price¥7,263.00
  5. Support¥7,249.33−0.19%3 touches, last on August 13, 2026
  6. Support¥6,817.50−6.13%2 touches, last on September 24, 2026

Volatility and risk

Over the last year it has moved little with the Nikkei 225.

Beta (1 year) vs Nikkei 225
0.12
Volatility (60 sessions, annualised)
32.7%
Largest fall in the last year
−42.43%

In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Chugai Pharmaceutical: seasonality

Average monthly price change over 37 years

+2.0%Jan+1.8%Feb+1.8%Mar+2.3%Apr−0.4%May+1.4%Jun+0.5%Jul−0.0%Aug+0.3%Sep+1.3%Oct+0.2%Nov−0.5%Dec

Over the last 37 years, the strongest month for Chugai Pharmaceutical has been April: +2.33% on average, positive in 19 years out of 37. The weakest has been December: −0.45% on average, positive in 17 years out of 36. November, the current month, has been positive in 18 years out of 36 (+0.24% on average).

Show chart data
MonthAverageMedianPositive years
January+1.99%0.00%17 of 36
February+1.78%+1.50%21 of 37
March+1.78%+1.57%22 of 37
April+2.33%+0.85%19 of 37
May−0.38%−1.83%16 of 37
June+1.39%+1.18%20 of 37
July+0.46%+0.86%20 of 37
August−0.03%0.00%18 of 37
September+0.25%−0.20%17 of 37
October+1.28%−1.88%15 of 37
November+0.24%+0.15%18 of 36
December−0.45%−0.61%17 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Chugai Pharmaceutical and its competitors

Chugai Pharmaceutical sells its medicines to customers in Japan and in markets across the world, and it researches, develops, manufactures, imports and exports pharmaceuticals in both. Its product range includes oncology products such as Avastin, Herceptin, Tecentriq, Alecensa, Polivy and Lunsumio, along with Hemlibra, Evrysdi, Mircera, Actemra, Enspryng, PiaSky, Vabysmo and Tamiflu. Among its partnerships, the company is deploying an agentic AI platform with Phylo, Inc. to support biomedical research in drug discovery.

Headquarters
Chuo, Japan
Employees
5,104
Founded
1925
Chief executive
Osamu Okuda
Chugai Pharmaceutical and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Chugai Pharmaceutical4519$76.25B48.3%24.1−7.89%
Otsuka Holdings4578$41.01B18.0%17.0+9.88%
Daiichi Sankyo4568$32.83B12.6%18.8+5.65%
Astellas Pharma4503$30.89B23.5%12.8+18.37%
CSPC Pharmaceutical Group1093$11.47B27.9%10.8+1.72%
BayerBAYN$61.54B16.5%—+48.87%

Same industry or related industries, similar size. Compare Chugai Pharmaceutical with its competitors · Full profile